Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study (Q90224620)

From Wikidata

Jump to navigation Jump to search

scientific article published on 30 November 2018

Language	Label	Description	Also known as
English	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study	scientific article published on 30 November 2018

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

squamous cell carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

0 references

Barbara Burtness

11

object named as

Barbara Burtness

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

1

object named as

Ezra E W Cohen

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Kevin J Harrington

15

object named as

Kevin J Harrington

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Denis Soulieres

2

object named as

Denis Soulières

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

5

object named as

Lisa Licitra

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

14

object named as

Ramona F Swaby

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

author name string

Christophe Le Tourneau

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

José Dinis

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Myung-Ju Ahn

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Ainara Soria

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Jean-Pascal Machiels

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Nicolas Mach

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Ranee Mehra

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Pingye Zhang

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Jonathan Cheng

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

KEYNOTE-040 investigators

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

publication date

30 November 2018

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

393

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

10167

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

156-167

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The Efficiency of Cox's Likelihood Function for Censored Data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative analysis of two rates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2931999-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(18)31999-8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30509740%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q90224620&oldid=2235409009"